Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 04 Apr 2012 Actual patient number added 31 according to ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.